Insulet (PODD) Stock Forecast & Price Target

$233.10

+1.90 (+0.82%)

(As of 10/11/2024 08:51 PM ET)

Insulet - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
3

Buy
13

Based on 16 Wall Street analysts who have issued ratings for Insulet in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, and 13 have given a buy rating for PODD.

Consensus Price Target

$234.60
0.64% Upside

According to the 16 analysts' twelve-month price targets for Insulet, the average price target is $234.60. The highest price target for PODD is $285.00, while the lowest price target for PODD is $184.00. The average price target represents a forecasted upside of 0.64% from the current price of $233.10.

Get the Latest News and Ratings for PODD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Insulet and its competitors.

PODD Analyst Ratings Over Time

Type	Current Forecast 10/15/23 to 10/14/24	1 Month Ago 9/15/23 to 9/14/24	3 Months Ago 7/17/23 to 7/16/24	1 Year Ago 10/15/22 to 10/15/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	15 Buy rating(s)	10 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$234.60	$225.29	$239.18	$279.07
Forecasted Upside	0.64% Upside	-3.67% Downside	18.76% Upside	110.81% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

FREE investing Class TOMORROW + 2 FREE Bonuses (Ad)

Over the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stocks that outperform the market. It helps me understand which stocks are worth investing in now…AND which ones you should avoid at all costs! Tomorrow, during my LIVE intro to investing class online, my team will show you how exactly how it works

[YES, I'D LIKE TO REGISTER FOR CHARLES PAYNE'S UPCOMING INTRO TO INVESTING CLASS NOW!]

PODD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PODD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Insulet Stock vs. The Competition

Type	Insulet	Medical Companies	S&P 500
Consensus Rating Score	2.81	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	0.64% Upside	10,372.52% Upside	6.89% Upside
News Sentiment Rating	Positive News See Recent PODD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/1/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$250.00 ➝ $275.00	+18.98%
9/25/2024	Canaccord Genuity Group 1 of 5 stars		Boost Target	Buy ➝ Buy	$236.00 ➝ $269.00	+12.26%
9/17/2024	Piper Sandler 2 of 5 stars		Boost Target	Overweight ➝ Overweight	$230.00 ➝ $285.00	+21.85%
8/12/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$200.00 ➝ $220.00	+20.75%
8/9/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Thibault Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$270.00 ➝ $250.00	+33.48%
8/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$211.00 ➝ $223.00	+22.14%
Get the Latest News and Ratings for PODD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.
6/10/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Positive ➝ Mixed
5/30/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$235.00	+36.43%
5/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$218.00 ➝ $213.00	+25.92%
5/10/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$255.00 ➝ $260.00	+46.48%
5/7/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform	$200.00	+13.38%
2/23/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$190.00 ➝ $225.00	+19.78%
2/5/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$163.00 ➝ $208.00	+7.39%
12/21/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$180.00 ➝ $238.00	+14.44%
12/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$185.00 ➝ $234.00	+21.75%
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
10/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$184.00	+35.83%
8/24/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$365.00 ➝ $295.00	+56.48%
8/9/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$350.00 ➝ $300.00	+30.61%
8/9/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$375.00 ➝ $330.00	+38.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:19 AM ET.

PODD Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Insulet is $234.60, with a high forecast of $285.00 and a low forecast of $184.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares.
: According to analysts, Insulet's stock has a predicted upside of 0.64% based on their 12-month stock forecasts.
: Insulet has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Piper Sandler, and UBS Group in the past 90 days.
: Analysts like Insulet more than other "medical" companies. The consensus rating score for Insulet is 2.81 while the average consensus rating score for "medical" companies is 2.79. Learn more on how PODD compares to other companies.